Galectin-1 (Gal-1), a carbohydrate-binding protein whose secretion is enhanced by hypoxia, promotes tumor aggressiveness by promoting angiogenesis and T cell apoptosis.
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Introduction:
Galectins (Gal) are members of a large carbohydrate binding lectins that share a highly conserved carbohydrate recognition domain (CRD) that is responsible for β-galactoside binding 1 . Recently, several galectins, specifically Gal-1, -3 and -9 have been implicated to play a role in cancer progression 2 . Although included in the same family, these three galectins are different from each other in size, tissue distribution and function 3 . Gal-1 is considered to be the 'proto-type' galectin that has one CRD and can form homodimers, whereas Gal-3 and -9 are part of different galectin subgroups 3, 4 . While the majority of Gal-1 is secreted into the extracellular matrix through a unconventional pathway, independent of the endoplasmic reticulum/Golgi route [4] [5] [6] [7] , it can also be found in the cytoplasm and the nucleus 2, 8 . Gal-1 is expressed in many tumor types including astroctyoma, melanoma, protstate, thyroid, colon, bladder and ovary carcinomas 8, 9 , and its expression correlates with tumor aggressiveness and metastasis [10] [11] [12] [13] . In lung cancer, increased Gal-1 expression is closely associated with larger tumors, more nodal metastasis and lower overall survival 14 .
Gal-1 is well known for its roles in modulating T-cell homeostasis, especially during development in the thymus and after stimulation at the periphery 15, 16 . However, the exact mechanism by which this protein promotes tumor aggressiveness is not well elucidated. It has been suggested that Gal-1 is involved in various pathological processes such as tumor cell proliferation Author Manuscript Published OnlineFirst on May 5, 2011; DOI: 10.1158/0008-5472.CAN-10-4157 Thijssen et al. has demonstrated that an anti-angiogenic peptide (anginex) binds to Gal-1 in endothelial cells and this interaction resulted in a reduction of endothelial cell proliferation and migration 24 . Another study showed that tumor growth and in-vivo angiogenesis are impaired in Gal-1 null mice, suggesting that angiogenesis is a major function of Gal-1 in tumor development 25 . In contrast, Rubinstein et al. demonstrated that the level of Gal-1 secretion in cultured supernatant correlated with the extent of tumor-induced T-cell death in both murine and human melanoma cells. Targeted inhibition of Gal-1 expression in-vivo rendered the mice resistant to tumor challenge, which is a process that requires functional CD4 + and CD8 + T-cell response 23 . These results suggest that Gal-1 contributes to tumor immune privilege by modulating survival of T-cell subsets.
We have previously found that Gal-1 secretion is significantly enhanced under hypoxia in tumor cells and its tissue expression could be used to assess treatment outcome in a large cohort of head and neck cancer patients. In addition, we noted an inverse relationship between tumor Gal-1 protein expression and the level of intratumoral T-cells in these tumors, suggesting that Gal-1 is a negative regulator of T-cell activation and survival in human tumors 26 . In this current study, we investigate the role of tumor versus host Gal-1 on tumor progression and metastasis. Additionally, the contribution of Gal-l's immunomodulatory versus proangiogenic function on tumor progression is also evaluated. Lewis lung carcinoma (LLC) tumors cells with high (control) and low Gal-1 (shGal-1) expression were implanted into Gal-1 wild-type (WT) and Gal-1 null (Gal-1 -/-) mice. We found that the expression of tumor Gal-1, rather than that of the host, was essential for tumor growth and spontaneous metastasis. Lung metastasis was only found 5 in mice bearing Gal-1 expressing tumors and not in the mice bearing shGal-1 tumors.
These results remained consistent even when the all tumors were allowed to reach to a comparable size. The effect of Gal-1 on intratumoral T-cell apoptosis and angiogenesis were also examined. We showed that the effect of Gal-1 on tumor growth and metastasis is dependent on the host immune function and its pro-angiogenic effect is no longer evident when T-or B-cell functions are removed in immune-deficient mice.
Materials and methods:
Generation of stable shGal-1 cells A pLKo.1 plasmid with a shRNA sequence: CCGGCCTACACTTCAATCCTCGC TTCTCGAGAAGCGAGGATTGAAGTGTAGGTTTTT was use to generate shGal-1 lentivirus (Thermo Scientific Open Biosystems, Hunstville, AL). Another pLKo.1 shRNA plasmid with a scramble (Scr) sequence (Addgene Inc., Cambridge, MA):
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGG GCGACTTAACCTTAGG was used as a negative control. Generation of Scr and shGal-1 lenti-viral particles were performed using the Trans-Lentiviral Packaging system (Thermo Scientific Open Biosystems, Huntsville, AL) following the manufacturer's suggested protocol. Gal-1 expression is detected by Western Blot analysis. Equal amounts of total protein were electrophoresed on 12.5% SDS polyacrylamide gel and incubated overnight at 4°C with goat anti-Gal-1 antibody (1:1000; R&D Systems, Minneapolis, MN). Following this incubation, membranes were probed with the HRP-conjugated anti-goat (1:10000; Invitrogen, Carlsbad, CA) and ECL detection (Amersham Biosciences, NJ. USA). The cell lysis buffer is used as a negative control and recombinant mouse Gal-1 is used as a May 5, 2011; DOI: 10.1158/0008-5472.CAN-10-4157 6 positive control (1 μg; R&D Systems, Minneapolis, MN). The membranes were also stained with mouse anti-β-actin antibody (1:1000; Sigma-Aldrich, St. Louis, MO) as a loading control. The secondary detection for β-actin with HRP-conjugated anti-mouse (1:10000; Invitrogen, Carlsbad, CA) followed the same procedures as mentioned above.
In addition, Scr cells and shGal-1 cells were plated in triplicates of 5000 cells/plate and allowed to proliferate for 6 days, the cell numbers were quantified every 2 days.
Mouse tumor models
All animal procedures were approved by the Institutional Animal Care and Use The WT and Gal-1 null mice were inoculated subcutaneously with either 2x10 5 Scr cells or shGal-1 cells at 2 month of age. A total of 60 mice were used for this study:
Gal-1 null/Scr (n = 15), Gal-1 null/shGal-1 (n = 15), WT/Scr (n = 15) and WT/shGal-1 (n = 15). The animals were euthanized when the tumor volume reached ~ 1.0 -2.0 cm 7 10% of the total body weight. Separate experiments were also performed to collect tissue at earlier time-points post-implantation. Following 48 hours of treatment, the T-cells were collected and analyzed through FACS.
Hypoxprobe-1 (pimonidazole) detection
A separate group of WT (n = 5) and Gal-1 null (n = 5) mice were used to detect 
Statistical analyses
Data are expressed as mean ± SEM. Statistical analysis was performed using IBM SPSS 19 software (SPSS Inc., Chicago, IL). A two-way ANOVA and post-hoc Tukey's test was used determine the significant differences of the tumor growth rates between mice strain and treatment groups. Lung metastases, TUNEL and CD31 measurements was analyzed with the unpaired Student's T-test. A p-value ≤ 0.05 is considered to be statistically significant. littermates. The wild-type (380 bp) and knockout (280 bp) genotypes were confirmed by PCR analysis (Fig. S1b) . Scr and shGal-1 LLC cells were implanted in the flank of either WT or Gal-1 null mice to form subcutaneous tumors. Four groups of mouse/tumor were generated: Gal-1 WT/Scr (high Gal-1 expression in both host and tumor), Gal-1 null/Scr (no host Gal-1 expression, high in tumor), Gal-1 WT/shGal-1 (normal host Galexpression, low in tumor) and Gal-1 null/shGal-1 (low Gal-1 expression in both). The mice were sacrificed in two different cohorts. In the first cohort, all four groups were euthanized at the same time, around day 22 when the difference in tumor size between the groups was the largest. In the second cohort, the tumors were allowed to reach the maximum comparable volume of approximately 1.0 -2.0 cm 3 for all 4 groups then sacrificed. This means that four groups were sacrificed at different time points due to differential tumor growth rate. Fig. 1a shows that the rate of tumor growth is significantly delayed by knocking down tumor but not host Gal-1 (this experiment was performed two times). In fact, scramble control tumors (Scr) grew slightly faster in Gal-1 null mice than in Gal-1 WT mice. However, shGal-1 tumors grew significantly slower than Scr tumors in either host with the slowest rate noted in the null mice. The difference in the tumor growth rate in- vivo was not due to an aberrant effect of knocking down Gal-1 on cell proliferation since in-vitro growth curves showed similar growth rate between parental, Scr and shGal-1 cells (Fig. 1b) . Moreover, Ki67 staining of the tumor showed similar level of Ki-67 positive cells in Scr and shGal-1 tumors (Fig. 1b) .
Interestingly, tumor Gal-1 expression also influenced the development of spontaneous lung metastases when the tumors were grown in the flank of these mice, as quantified by light microscopy. In this experiment, the tumors in the four groups were allowed to reach the maximal allowable size size (see above). The animals were then sacrificed and the lungs were examined for spontaneous metastasis. None of the mice inoculated with shGal-1 tumor cells developed lung metastasis (even when the tumor size were > 1.0 cm 3 ) whereas Scr cells developed on the average 4.1 ± 0.4 metastases/lung section in the WT mice and 2.3 ± 0.4 metastases/lung section in Gal-1 null mice. We also confirmed that shGal-1 cells continued to maintain low level of Gal-1 expression in vivo by immunoblot and immunohistochemical staining of tumor tissue (Fig. S1c ).
Furthermore Gal-1 staining of the lung sections from WT mice bearing Scr tumors showed that Gal-1 protein expression is significantly more intense in the lung metastases than in the adjacent normal lung tissues (Fig. S4) . Our result showed that reduction of Gal-1 protein in the tumor but not the host suppressed both tumor growth and distant metastasis. DOI: 10.1158/0008-5472.CAN-10-4157 Gal-1 has been shown to promote tumor growth through several mechanisms. One major mechanism focuses on its inhibitory effect of immune tumor surveillance by promoting intratumoral T-cell apoptosis 23 , blocking T-cell activation 27 and inhibiting secretion of pro-inflammatory cytokines. Another major mechanism invokes its proangiogenic effect 25 . Here we aimed to elucidate some of these mechanisms in our model Like others, we found that exposing splenocytes to recombinant Gal-1 resulted in increased T-cell apoptosis (by TUNEL) and suppressed T-cell division (measured by CSFE), especially when these cells were activated by Concavalin A (Fig. S2) . We then proceeded to examine tumor growth and spontaneous metastasis for both Scr and shGal-1 tumor cells in several immune-compromised mouse models, hence eliminating the immunomodulatory effect of Gal-1. These included Nod.Cg-Prkdc Fig. 2a , both Scr and shGal-1 tumors grew at the same rate in these immunecompromised mice. Likewise, the number of spontaneous lung metastases was similar for Scr and shGal-1 tumors (Fig. 2b: 19.8 ± 3.8 metastases for Scr versus 17.4 ± 2.8 mets for shGal-1). These data strongly indicated that the Gal-1's enhancing effect on tumor growth and metastasis that was previously noted in immune-competent mice was most likely due to its immunomodulatory function.
Mechanism of tumor Gal-1 on cell growth and metastasis
Immunomodulation via T-cell apoptosis
To support this observation, we stained the mouse tumors for CD3, a pan-T cell marker. As shown in Fig. 3a , there was more CD3 staining in the shGal-1 tumors than in the Scr tumors, suggesting less T-cell death. We then co-localized CD4 (T-helper cell marker) and CD8 (cytotoxic T cell marker) with TUNEL and quantified the number of DOI: 10.1158/0008-5472.CAN-10-4157 apoptotic T-cells within the tumors. As expected, there was significantly more T-cell apoptosis in the Scr tumors than in shGal-1 tumors in the WT mice (Fig. 3b) . The CD8 + T-cell death in the Scr tumors (n = 4, 61.2 ± 8.3%) was significantly greater than that in shGal-1 tumors (n = 4, 15.3 ± 4.6%). Similarly, the CD4 + T-cell death in the Scr tumors (n = 4, 46.2± 7.5%) was higher than in shGal-1 tumors (n = 4, 3.9 ± 1.5%). Similar observation was also made in tumors growing in Gal-1 null mice (Fig. S3a) .
Since hypoxia induces Gal-1 secretion, we hypothesize that we would observe more T-cell apoptosis in the hypoxic regions of Gal-1 expressing tumors but not in shGal-1 tumors. We colocalized CD4, CD8, TUNEL and pimonidazole (a hypoxia marker) in the WT/Scr and Gal-1 null/shGal-1 tumors (Fig. S5) . Although we saw minimal T-cell apoposis within the hypoxic regions of either tumors, we noted more 
Effects of Gal-1 on Angiogenesis
Several studies have indicated that Gal-1 also has a pro-angiogenic function, which may primarily drive tumor growth and metastasis 24, 25 . Therefore, we evaluated the microvessel density count (MVD) by CD31 staining on tumor tissues collected at three different time points. For the first time point, both shGal-1 and Scr tumors were implanted at the same time (day 0) and sacrified at day 22 when the tumor growth differential was the largest between the two tumor groups (n = 3/group). For the second time point, we sacrified the mice when the tumors reached the maximum allowable progression is yet to be determined.
Here we show that tumor Gal-1 is more critical in promoting tumor growth and metastasis and that host Gal-1 is less essential in our model. Depleting Gal-1 in the tumor resulted in a significant tumor growth delay and aborted the development of spontaneous lung metastasis in subcutaneously implanted tumors. Tumors expressing Gal-1 grew at the same rate and had similar numbers of lung metastases regardless of the host phenotype (Gal-1 WT and null mice), indicating that tumor Gal-1 is sufficient to promote tumor growth and distant spread in these mice. In contrast, a much smaller tumor growth delay effect was noted when host Gal-1 was removed and it was only observed when Gal-1 was down-regulated in the tumor. Since presumably the same protein was produced and secreted by the tumor and the host cells, a possible explanation for our findings is the difference in the level of Gal-1 protein generated and secreted between the tumor and the host normal tissues. Appreciably higher expression of Gal-1 mRNA has been reported for human lung cancers when compared to matched normal lung tissues ( Fig. S4) . Moreover, our previous study has shown that hypoxia, which a common phenomenon in solid tumors, significantly enhanced the secretion of Gal-1 protein from tumor cells. Since hypoxia is not present in most normal tissues, hypoxia induced Gal-1 secretion from the tumor may also contribute to the differential effect noted for tumor and host Gal-1. Finally, the activity of this protein is enhanced when it forms homodimers, which are more likely to occur when it is secreted at high levels.
Several strategies presently exists for targeting Gal-1 activity; these include blocking antibodies to deplete Gal-1 and to interfere with its ligand binding, natural polysaccharides or synthetic glycodendrimers that complete with its glycan-binding ability or the peptide anginex, which mainly binds to Gal-1 in endothelial cells 24, 33 . If
Gal-1 pro-angiogenic activity is the most crucial for tumor growth and metastasis, then targeting Gal-1 with anginex may be better than other approaches as it will be more specific with less normal tissue toxicity. On the other hand, if its immunomodulatory function is more crucial, then antibody or polysaccharide targeting approach may be more effective. Here we showed that Gal-1 immunomodulatory function may be more critical than its pro-angiogenic function in our tumor model. In immune-competent mice, there was significantly greater T-cell apoptosis for both CD4 In summary, using genetic models, we show tumor Gal-1 is more essential than host Gal-1 in enhancing tumor growth and metastasis, which appears to be mediated via its immunomodulatory function. These findings have broad implications in developing novel targeting strategies for Gal-1 in cancer. 
